Clinical Trial: A Phase II Study Evaluating Andamertinib in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR PACC or EGFR L861Q Mutations.

U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336732) titled 'A Phase II Study Evaluating Andamertinib in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR PACC or EGFR L861Q Mutations.' on Dec. 18, 2025.

Brief Summary: This study is an open-label, multicenter phase IIclinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib (phase II) in previously untreated participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR PACC mutations or EGFR L861Q mutations.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Non-Small-Cell Lung Cancer

Intervention: DRUG: PLB1004

PLB1004 is a capsule in the form of 80m...